The Centers for Medicare & Medicaid Services recently issued a proposed rule (CMS-1645-P) outlining proposed FY 2017 Medicare payment rates and quality programs for skilled nursing facilities. CMS will accept comments on the proposed rule until...
High-dose oral vitamin D supplements taken for 1 year significantly improved cardiac structure and function in patients with chronic heart failure secondary to left ventricular systolic dysfunction, according to results from a new study.
Many readers are familiar with the Center for Medicare & Medicaid Innovation and Medicare and Medicaid Coordination Office (CMMI-MMCO) ongoing project on reducing hospitalizations in nursing home residents. Now finishing its fourth year, recent...
ORLANDO, FL — More must be done in post-acute and long-term care to “resist and dismantle the prescription cascade” that occurs when side effects of medications are treated by prescribing additional drugs rather than lowering doses or even...
ORLANDO, FL — The Society House of Delegates (HoD) passed several significant resolutions and white papers at its recent meeting. “It was an incredibly productive and interesting meeting. We made tremendous progress on several key issues within a...
ORLANDO, FL — Susan M. Levy, MD, CMD, gave no doubt that she was ready to take the reins as president for AMDA – The Society for Post-Acute and Long-Term Care in the coming year.
ORLANDO, FL — When a 65-year-old frail long-term care resident was sent to the ED for the third time in 3 months for lower gastrointestinal bleeding, geriatrics fellow Scott Hanson, DO, was impelled to investigate.
ORLANDO, FL — In a health care world where hospital stays and readmission can cost both acute and PALTC facilities dearly, PALTC practitioners may have the recipe for safe, high-quality, cost-effective care.
ORLANDO, FL — Leadership, passion, and vision are not uncommon qualities possessed by PALTC practitioners. Each year, AMDA – The Society for Post-Acute and Long-Term Care Medicine honors the best of the best with three awards: Medical Director of...
The Food and Drug Administration has approved pimavanserin for the indication of hallucinations and delusions associated with psychosis in Parkinson’s disease.
